Representational AI-image
No child with SMA should face an interruption in treatment due to barriers to the availability of medicines, the association’s Kerala state president Dr M N Menon and state secretary Dr Roy R Chandran said in a statement.
Kozhikode : Indian Medical Association (IMA) Kerala has said that the safety of children, continuity of treatment and public health interests should take priority over disputes between brands in matters related to medicines for SMA. appropriate specialist supervision and follow-up monitoring should also be ensured, it said While the use of lower-cost medicines could help make treatment accessible to more children. IMA Kerala said govt should strengthen long-term mechanisms to ensure continued treatment for all eligible children, irrespective of their families’ financial circumstances. Ensuring access to quality medicines at affordable prices and uninterrupted treatment would provide the greatest relief to patients and their families, the association said.
The association expressed support for the health department’s efforts to reduce the cost of treatment for rare diseases and extend access to treatment to more children.